GMS infectious diseases最新文献_第3页

Canibacter oris - a fairly unknown pathogenic agent of bite wound infections. 口卡尼杆菌-一种相当未知的咬伤感染致病菌。

GMS infectious diseases Pub Date : 2021-04-22 eCollection Date: 2021-01-01 DOI: 10.3205/id000070

Herbert Hof, Konrad Bode, Falko von Stillfried

引用次数: 0

Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study. 在败血症和血流感染中引入快速识别细菌和早期抗生素敏感性试验后的临床和经济改进。现象研究的结果。

GMS infectious diseases Pub Date : 2020-12-15 eCollection Date: 2020-01-01 DOI: 10.3205/id000069

Michael Wilke, Wolfgang Heinlein, Luis Stiefenhofer, Klaus-Friedrich Bodmann

{"title":"Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study.","authors":"Michael Wilke, Wolfgang Heinlein, Luis Stiefenhofer, Klaus-Friedrich Bodmann","doi":"10.3205/id000069","DOIUrl":"https://doi.org/10.3205/id000069","url":null,"abstract":"Background: Sepsis and bloodstream infections pose severe challenges in intensive care. Early reliable diagnosis is the key to successful therapy. The objective of the study presented here was to investigate the clinical and economical effects of the new PhenoTM BC test, which allows bacteria identification (ID) and antimicrobial susceptibility testing (AST) in approximately 7 hours after a blood culture becomes positive (BC+). Methods: Historically controlled interventional study. Population: patients with BC+ and ICU admission. Inadequate initial antimicrobial therapy (IAT) is need of therapy change based on result. Prospectively the new test was used in addition. Primary endpoint: time-to-result in hours. Contribution margin (CM) i.e. revenue - costs was computed. All patients formed the intention-to-treat population (ITT). Patients with complete cost data formed the modified ITT group (mITT). CM results were calculated for mITT and PP. Further analyses: length-of-stay (LOS) and mortality. Results: 223 historical and 200 prospective patients were included. Time to result (ITT) was shortened by 51.1 hours (83 vs. 31.9; p<0.001). Overall savings (mITT) were 257,100 € (-301,264 € vs. -44,164 €). 143 of 181 (79%) patients had a test performed, 126 of 143 (88%) having a clinically useable result. 40 (32%) had IAT vs. 65 (29%) in the historic cohort. Median time to AST in PP was shortened by 61.7 hours (89.5 vs. 27.8; p<0.001). LOS was shortened 7 days (28 vs. 19; p=0.226) and mortality was 8% (40.5% vs. 32.5%; p=0.440) lower. Median CM +3,074.80 € per case (-2,350.50 € vs. +724.70 €; p=0.040). Conclusion: The new PhenoTM ID+AST test leads to faster and clinically meaningful results and saves money by shortening LOS on the ICU.","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc25"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39098271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers in urinary tract infections - which ones are suitable for diagnostics and follow-up? 尿路感染的生物标记物--哪些适合用于诊断和随访？

GMS infectious diseases Pub Date : 2020-11-26 eCollection Date: 2020-01-01 DOI: 10.3205/id000068

József Horváth, Björn Wullt, Kurt G Naber, Béla Köves

{"title":"Biomarkers in urinary tract infections - which ones are suitable for diagnostics and follow-up?","authors":"József Horváth, Björn Wullt, Kurt G Naber, Béla Köves","doi":"10.3205/id000068","DOIUrl":"10.3205/id000068","url":null,"abstract":"Introduction: Urinary tract infections (UTIs) are one of the most common infections worldwide. Under special circumstances, clinicians must rely on laboratory findings, which might have a weak predicting value, misguiding the practitioners and leading to incorrect diagnosis and overuse of antibiotics. Therefore, there is an urgent need for reliable biomarkers in UTIs. Methods: We performed a literature search for biomarkers used in UTIs from January 1999 until May 2020. We used \"urinary tract infection\" and \"biomarker\" as the main key words in the PubMed, Medline and Cochrane databases. After peer review, we excluded the duplicates and identified the suitable articles, from which we collected the data and divided the available biomarkers into 5 groups: i) conventional markers; ii) promising, thoroughly studied biomarkers; iii) promising biomarkers that need further studies; iv) biomarkers of unknown significance; v) controversial, not useful markers. Results: We found 131 articles, mostly from the paediatric population. Neutrophil gelatinase-associated lipocalin (NGAL) and interleukins (IL) have a leading role in diagnosing and differentiating UTIs based on a lot of observational, comparative trials. Heparin Binding Protein (HBP), Lactoferrin (LF), Heat-Shock Protein-70 (HSP-70), Human Defensin-5 (HD-5), Lipopolysaccharide Binding Protein (LBP) and mass spectrometry studies are promising, but confirming data are lacking. The measurable components of the innate immune system and local host cell response could be appropriate biomarkers, but their significance is currently unknown. Conclusions: Conventional biomarkers for UTIs have low specificity. The use of urinary NGAL and interleukins could improve the sensitivity and specificity of laboratory diagnosis of UTIs.","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc24"},"PeriodicalIF":0.0,"publicationDate":"2020-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38706265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wound infection caused by Photobacterium damselae in a 32-year-old woman: case report and review of the literature. 32岁女性少女光杆菌致伤口感染1例报告及文献复习。

GMS infectious diseases Pub Date : 2020-11-17 eCollection Date: 2020-01-01 DOI: 10.3205/id000067

Percy Schröttner, Eric Tille, Christian Lück, Boyke Bunk

引用次数: 1

Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays. 五种商业免疫测定法评价门诊患者SARS-CoV-2-IgG反应

GMS infectious diseases Pub Date : 2020-09-16 eCollection Date: 2020-01-01 DOI: 10.3205/id000066

Nele Wellinghausen, Meike Voss, Ralitsa Ivanova, Susanne Deininger

{"title":"Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays.","authors":"Nele Wellinghausen, Meike Voss, Ralitsa Ivanova, Susanne Deininger","doi":"10.3205/id000066","DOIUrl":"10.3205/id000066","url":null,"abstract":"Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While high sensitivity has been reported in hospitalized COVID-19 patients, little is known about the performance of the assays in ambulatory patients. Therefore, we evaluated the SARS-CoV-2-IgG response in 51 SASR-CoV-2-PCR-confirmed outpatients with five commercial immunoassays. The sensitivity in serum samples, collected at a median of 24 days after onset of symptoms, detected by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun), EDI™ Novel Coronavirus COVID-19 IgG ELISA (Epitope Diagnostics), Liaison® SARS-CoV-2 S1/S2 IgG (Diasorin), SARS-CoV-2 IgG on the Architect™ i2000 (Abbott), and Elecsys® Anti-SARS-CoV-2 (IgM/IgA/IgG) on the cobas™ e801 (Roche) was 84.3%, 78.4%, 74.5%, 86.3%, and 88.2%, respectively. The sensitivity in serum samples, collected >20 days after onset of symptoms, varied between 75.0% and 90.0%, and in samples, collected at least 28 days after onset of symptoms, did not increase, except in the Anti-SARS-CoV-2-ELISA IgG by Euroimmun (90.0%). There was not an obvious association between the type of the antigen (N versus S protein) and the overall sensitivity of the assays. Our results show significant individual differences of the IgG response against SARS-CoV-2, additionally confirmed in three patients with follow-up serum samples and seven asymptomatic but PCR-positive contact persons. In conclusion, our study shows that commercially available immunoassays detect SARS-CoV-2-IgG or total antibodies in outpatients with a satisfying sensitivity, but lower than that reported for hospitalized patients. In asymptomatic persons the SARS-CoV-2-IgG response may even be absent in a relevant percentage of persons.","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"8 ","pages":"Doc22"},"PeriodicalIF":0.0,"publicationDate":"2020-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38429556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Immunology of urinary tract infections. 尿路感染免疫学。

GMS infectious diseases Pub Date : 2020-05-12 eCollection Date: 2020-01-01 DOI: 10.3205/id000065

José Antonio Ortega Martell

引用次数: 2

Calculated initial parenteral treatment of bacterial infections: Safety and tolerabilty. 细菌感染的计算初始肠外治疗：安全性和耐受性

GMS infectious diseases Pub Date : 2020-03-26 eCollection Date: 2020-01-01 DOI: 10.3205/id000060

Ralf Stahlmann, Hartmut Lode

引用次数: 0

Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract. 细菌感染的计算肠外初始治疗：肾脏和泌尿生殖道感染。

GMS infectious diseases Pub Date : 2020-03-26 eCollection Date: 2020-01-01 DOI: 10.3205/id000056

Reinhard Fünfstück, Udo Hoyme, Kurt Naber, Adrian Pilatz, Sören Schubert, Florian Wagenlehner

引用次数: 0

Calculated parenteral initial treatment of bacterial infections: Introduction and antibiotics. 细菌感染的肠外初始治疗计算：介绍和抗生素。

GMS infectious diseases Pub Date : 2020-03-26 eCollection Date: 2020-01-01 DOI: 10.3205/id000063

Klaus-Friedrich Bodmann, Michael Kresken, Béatrice Grabein, Pascal M Dohmen, Michael Wilke

引用次数: 0

Calculated initial parenteral treatment of bacterial infections: Bacterial endocarditis. 计算细菌感染的初始肠外治疗:细菌性心内膜炎。

GMS infectious diseases Pub Date : 2020-03-26 eCollection Date: 2020-01-01 DOI: 10.3205/id000052

Pascal M Dohmen, Klaus Friedrich Bodmann, Wolfgang Graninger, Pramod Shah, Florian Thallhammer

引用次数: 4